Imsidolimab is a monoclonal antibody that inhibits interleukin-36 receptor signaling and is administered intravenously.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/company-files-approval-biologic-treating-generalized-2026a100060x?src=rss
Author :
Publish date : 2026-02-26 04:29:00
Copyright for syndicated content belongs to the linked Source.